Articles tagged with Cancer Relapse
Researchers identified a gene expression signature and inflammation patterns in normal tissue near the tumor to distinguish between patients with aggressive disease. The study paves the way for early identification of high-risk patients through blood or semen samples.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Melanie Rutkowski's pioneering research may lead to novel immunotherapy treatments for ovarian cancer by understanding how faulty cellular signaling interacts with the microbiome. The grant aims to enhance immune system's ability to kill cancer cells and improve patient outcomes.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
Researchers discovered glioblastoma cells use PRDM9 to survive chemotherapy and regrow tumors. By blocking PRDM9 or cutting off cholesterol supply, persister cells can be wiped out, improving survival in mice. This breakthrough offers new strategies for treating the deadliest brain cancer.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
The study found that a nine-month programme of supervised exercise improved muscle mass and strength, particularly in the arms and legs, and physical performance in patients with breast cancer that had spread to other parts of the body. Muscle mass increased by an average of 0.79 kg after three months and 0.32 kg after six months compa...
A global survey of nearly 4,000 young women with advanced breast cancer found that nearly half have children under 18 and face significant hardship. The study also revealed delays in seeking care, unmet psychosocial needs, and limited access to precision diagnostics.
Neuroblastoma is often difficult to treat due to its ability to enter a dormant state when the MYCN gene is located outside chromosomes. A new study proposes targeting these dormant tumor cells with a combination of chemotherapy and a second drug, showing promising results in mouse models.
Researchers from City of Hope will present novel cancer treatment approaches and combinations, including innovative combination therapies for breast, genitourinary, and gastrointestinal cancers. Additionally, they'll discuss the safety of readministering trastuzumab-deruxtecan to metastatic breast cancer patients with low-grade lung co...
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
AIC100 demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, including anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC). The therapy showed significant tumor shrinkage and disease control in 56% of patients.
A highly sensitive bone marrow test has shown to double survival rates for patients with AML mutations in NPM1 and FLT3 genes, allowing for early detection of potential relapse. This trial indicates that regular molecular testing can improve long-term survival rates by restarting treatment earlier.
A survey by Roswell Park Comprehensive Cancer Center found that 65% of Americans are unfamiliar with CAR T-cell therapy, a personalized cancer treatment option. The therapy involves extracting and engineering immune cells to recognize and kill cancer cells, with promising results in treating blood cancers.
Researchers at MD Anderson have made significant breakthroughs in understanding pancreatic cancer's evolutionary process and developing new treatment strategies. They also discovered that surgical resection can enhance antitumor response in patients receiving immune checkpoint therapy for advanced kidney cancer.
P4HA1 enzyme disrupts energy production in immune cells, weakening their ability to fight cancer. Inhibiting P4HA1 restores healthy immune cell function and sustains long-term immunity, showing promise in treating solid tumors.
Researchers developed a system to monitor tumor-informed circulating tumor DNA (ctDNA) after comprehensive genomic profiling (CGP), enabling accurate prediction of patient outcomes. The study showed that this approach can be effectively used in conjunction with CGP data to predict cancer relapse and treatment response, improving person...
A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.
More than 70 hematology researchers from the University of Miami Miller School of Medicine will showcase their work at the 66th ASH Annual Meeting & Exposition. Researchers from Sylvester Comprehensive Cancer Center are authors or co-authors on a significant number of posters presented during the event.
Researchers from the Sylvester Comprehensive Cancer Center presented their findings on the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes. Dr. Stephen D. Nimer received the 2024 ASH Mentor Award for his impact on hematology trainees.
Researchers at Montefiore Einstein Comprehensive Cancer Center have discovered a natural immune mechanism in mice that stops escaped cancer cells from developing into tumors elsewhere in the body. Alveolar macrophages recognize and interact with disseminated cancer cells, producing signals that keep them dormant.
A new CAR-T cell therapy targeting CD7 on leukaemia cells has shown promising results in treating T-ALL patients who have exhausted all standard treatment options. The therapy achieved complete remission in 16 out of 17 patients, with some remaining in remission for over five years.
A recent study published in Liver Cancer found that patients with diabetes mellitus and comorbid obesity are at a higher risk of liver cancer recurrence after resection. The risk is significantly higher for those with comorbid obesity, increasing by approximately 3.8 times over five years postoperatively.
A new study published in Nature has found that the type 2 immune response is positively correlated with long-term cancer remission, contradicting previous theories that it promotes tumor growth. The research used samples from pioneering clinical trials and revealed a statistically significant correlation between type 2 immune factors a...
A phase 1b/2 clinical trial found a combination of immunotherapy and FGFR inhibitor to be safe and tolerable in patients with locally advanced or metastatic bladder cancer. The treatment showed increased response rates, including 54% for patients with high FGFR mRNA expression.
A four-year grant will help researchers find new clues to the interplay between Down syndrome and myeloid leukemia, focusing on enhancing antileukemic activity of chemotherapy drug cytarabine. The goal is to identify a novel treatment strategy to improve patient outcomes and prevent relapses in ML-DS patients.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers at MedUni Vienna have identified AF1Q as a promising biomarker to predict gastric cancer recurrence risk. The study found that 97.8% of tumour samples had elevated AF1Q levels, associated with higher recurrence risk and lower survival chances.
The E1910 trial demonstrated a significant survival advantage with blinatumomab immunotherapy, improving overall and relapse-free survival in patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia. This finding contributed to the recent FDA approval of blinatumomab for these patients.
A blood test measures lymphocyte count to predict treatment response in relapsed multiple myeloma. Patients with higher lymphocyte counts experience better cancer control for longer periods.
A phase II clinical trial found that combining sEphB4-HSA with pembrolizumab improved outcomes in HPV-negative, EphrinB2-positive head and neck squamous cell carcinoma patients. The combination showed a favorable toxicity profile and activity, particularly among those with HNSCC.
A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.
A new liquid biopsy method analyzes gene fragments in the bloodstream to detect and track cancer, enabling oncologists to tailor treatment approaches to individual patients. This non-invasive test can help monitor treatment success, detect cancer recurrence, and improve patient quality of life.
A phase II clinical trial found trametinib effective in treating pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML), with seven of ten patients alive after two years. The treatment showed antitumor activity and downregulated inflammatory signaling, offering hope for JMML patients and their families.
A new 'armored' form of CAR T cell therapy, developed by University of Pennsylvania researchers, has shown significant responses in patients whose cancers don't respond to current CAR T cell therapies. The three-day manufacturing process also shortens treatment time for aggressive, fast-growing cancers.
Researchers discuss the benefits of CAR-T therapy in treating B-cell lineage acute lymphoblastic leukemia (B-ALL) in children. The therapy, tisagenlecleucel, has shown promising results and is now priced at $508,250, a more manageable cost compared to other gene therapies.
A study by the University of Gothenburg found that women with triple-negative breast cancer and high immune cell levels have a lower relapse risk after surgery. This suggests that these patients may not need chemotherapy, despite having faster-growing tumors and higher relapse rates than other breast cancers.
Researchers highlight the role of post-transcriptional RNA modifications in AML pathogenesis, identifying m6A and m7G regulators as potential therapeutic targets. Targeted therapies, including selective inhibitors and Traditional Chinese Medicine compounds, show promise in promoting cell differentiation and reversing AML phenotypes.
A simple urine test can reduce the number of cystoscopies required to follow up high-risk bladder cancer patients by more than half. The test monitors for recurrence of bladder cancer by measuring levels of five target mRNAs and was found to be effective in picking up cancer recurrence before any disease was visible through a cystoscopy.
Recent trials have shown that testing for tumour DNA in the blood can identify advanced bladder cancer patients who are less likely to relapse after surgery, allowing doctors to target treatments more effectively.
Researchers identify mitochondrial priming as a key driver of multi-drug resistance in relapsed acute myeloid leukemia. A new technique called dynamic BH3 profiling reveals anti-cancer drugs capable of overcoming resistance.
A research team at the University of Cologne has identified mechanisms governing drug response in small cell lung cancer. The study reveals that large populations of treatment-sensitive cells often hide numerous therapy-resistant cells that can multiply unchecked after successful treatment.
Researchers discovered genes encoding growth regulators normally not present in myeloid cells are expressed by leukaemic stem cells, allowing them to grow. Repurposed drugs targeting these receptors show promise in blocking stem cell growth and preventing disease relapse in specific types of AML.
Researchers identify a promising prognostic biomarker for lung cancer using circulating tumor DNA-based minimal residual disease detection. The study found that this method can effectively guide treatment decisions and predict recurrence risk, potentially modifying the lung cancer treatment paradigm.
Researchers found that high levels of FSP1 are associated with relapse after cisplatin treatment in head and neck squamous cell carcinoma. Targeting FSP1 can attenuate tumor stemness and downregulate invasion and metastatic rates, suggesting a potential new approach for treating drug-tolerant persister cancer cells.
A Phase 3 clinical trial found that combining testosterone-blocking drugs prevents cancer spread and extends treatment time in patients with relapsed prostate cancer. The approach is more effective than single-drug treatment in delaying cancer progression.
Researchers from Brazil discuss the management of refractory or relapsed classic Hodgkin lymphoma in adults, highlighting novel agents such as brentuximab vedotin and immunotherapy. The Brazilian healthcare system's constraints are also considered when making treatment decisions.
Researchers explore the properties of cytostatic persisters in cancer treatment, highlighting their therapeutic potential and challenges. The study suggests that targeting these persisters before resistance emerges can reduce cancer recurrence.
A VHIO-led study has identified DPPA3 as a regulator of dormant cancer cells and chemoresistance in colorectal cancer. High levels of DPPA3 are found to predict disease relapse, while HIF1 is proposed as a potential therapeutic target to sensitize CRC cells to chemotherapy.
A Rice University-led team of researchers has been awarded $45 million to develop a new sense-and-respond implant technology that could improve immunotherapy outcomes for patients with difficult-to-treat cancers. The technology, called THOR, aims to provide real-time data from the tumor environment to guide more effective therapies.
Scientists from IRB Barcelona have revealed how chromosomal instability activates a signalling pathway known as JAK/STAT, promoting caspase activity and DNA injury. This damage allows cells to escape from the primary tumour, thereby leading to metastasis.
A new approach to immunotherapy has shown long-term survival rates exceeding 50% in children with high-risk neuroblastoma. Stem cell transplantation from a parent provides a renewed immune system that responds better to immunotherapies, improving outcomes.
Researchers investigated H3K27me3 expression patterns in pediatric brain tumors, finding a global loss of this epigenetic mark in diffused midline glioma (DMG). This loss was associated with high relapse rates and poor survival, highlighting the potential for targeting H3K27me3 as an epigenetically guided cancer therapy.
Researchers report a case of a 15-year-old boy with recurrent intrathoracic synovial sarcoma who achieved partial response with BRAF inhibitor Vemurafenib treatment. The study highlights the importance of routine next-generation sequencing to drive treatment choice and investigate BRAF mutations in SS tumors.
A new study by researchers at Dartmouth Cancer Center shows that a combination of estrogen and PARP inhibitors can effectively treat advanced ER+ breast cancer by damaging cancer cells and preventing DNA repair. The treatment strategy has been shown to be effective regardless of BRCA1 or BRCA2 genetic mutations.
A team of researchers has identified a unique genetic signature in CAR T-cells that enables them to persist in the body for a longer time, leading to improved remission rates for children with leukaemia. This discovery provides a new understanding of why some CAR T-cells last longer and can help improve treatment outcomes.
Cancer cells can hide and escape therapies leading to recurrence. Researchers identify three possible mechanisms: cancer stem cells, polyploidy, and senescence. Combination treatments involving chemoradiation-induced transitory senescence and senolytic therapies may be effective in preventing repopulation.
Researchers have developed a new standard for preventing graft-versus-host disease (GVHD) after stem cell transplant, showing improved efficacy and reduced side effects compared to the current gold standard. The new regimen achieved higher rates of patient survival without GVHD complications, making it a more effective option for patie...
Researchers at UCL have developed base-edited T-cells that can fight leukemia, showing promise in a NHS clinical trial. Three patients with relapsed T-cell leukaemia were treated with the cells, with one patient experiencing complete remission after just four weeks.
Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.